MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters
-
Published:2024-03
Issue:
Volume:192
Page:110090
-
ISSN:0167-8140
-
Container-title:Radiotherapy and Oncology
-
language:en
-
Short-container-title:Radiotherapy and Oncology
Author:
van Overeem Felter Mette,
Møller Pia Krause,
Josipovic MirjanaORCID,
Bekke Susanne Nørring,
Bernchou Uffe,
Serup-Hansen EvaORCID,
Madsen Kasper,
Parikh Parag J.,
Kim Joshua,
Geertsen Poul,
Behrens Claus P.,
Vogelius Ivan R.,
Pøhl Mette,
Schytte Tine,
Persson Gitte Fredberg
Reference33 articles.
1. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer;Iyengar;JAMA Oncol,2018
2. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial;Ost;J Clin Oncol,2018
3. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study;Gomez;Lancet Oncol,2016
4. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial;Palma;Lancet,2019
5. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC;Wang;J Natl Cancer Inst,2022